Navigation Links
VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations

CHARLESTON, S.C., Nov. 9, 2011 /PRNewswire/ -- VaxyGen Assay Services, LLC, today announced that it has commenced business operations, providing custom assay services, immunoassays, and database services in support of biopharmaceutical and vaccine development. The Company offers customized solutions to meet basic, applied, and clinical research demands, providing unique in vitro assays in support of research and development of novel biopharmaceutical and vaccine products operating through its GLP compliant laboratory facilities to support biomarker/immunoassay evaluation and development needs.

Commenting on the launch of VaxyGen Assay Services, David Dodd, CEO, stated, "We believe that our clients are best served through the successful combination of the highest expertise and support of science and business.  Our clients are committed to delivering innovative, life enhancing products.  VaxyGen Assay Services was founded to ensure that our clients can consistently rely on us to deliver them the highest quality client service and scientific service in support of their biological assay service needs.  Our Management Team reflects this commitment – most importantly, through their demonstrated experience in delivering such value to clients."

Leading the scientific and technical expertise at VaxyGen Assay Services is Joseph E. Martinez, Ph.D., a recognized expert in flow cytometry and multiplexed immunoassay development. Joseph is a research biologist with 25 years of flow cytometry experience. Prior to the formation of the VaxyGen family of companies, he spent 13 years as the head of the flow cytometry laboratory within the Respiratory Diseases Section at the Centers for Disease Control and Prevention. He has served as the Director of Research and Laboratory Services for several biotech companies. He has developed multiplexed immunological assays for the flow cytometric, Luminex, and ELISA platforms. Dr. Martinez is the lead inventor for US patents related to multiplex immunoassays, and is a co-inventor for an immunological adjunct molecule.

About VaxyGen Assay Services, LLC & VaxyGen Holdings, LLC

VaxyGen Assay Services ( is a member of the VaxyGen Holdings, LLC ( family of companies, consisting of VaxyGen Vaccines, Ltd., VaxyGen Manufacturing Services, LLC, VaxyGen Assay Services, LLC and, VaxyGen Management Company, LLC.  In June, 2011, the formation of VaxyGen Vaccines, Ltd., was announced in conjunction with an exclusive strategic agreement signed with the Serum Institute of India (, providing a novel, new vaccine business focused on delivering affordable innovation to improve immunization against life threatening conditions.  In October, 2011, the formation of VaxyGen Manufacturing Services, LLC was announced in conjunction with an exclusive agreement signed with the Georgia State University Research Foundation, providing a unique business collaboration with the Georgia State University Biological Process Development and Research Laboratory.

Kathryn D. Gallagher
Director, Marketing & Operations
Tel: 843.789.5924; 1.888.753.7362

SOURCE VaxyGen Assay Services, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
2. Early Adopter of INFORM HER2 Dual ISH Assay Optimistic About Impact on Patient Care, Hospital Bottom Line
3. Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria
4. NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay
5. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
6. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
7. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
8. Calipers Microfluidic Technologies Enable 510(k) Approved Multiplexed Immunoassay System for Liver Cancer Risk Assessment
9. Reimbursement Rate Nearly Tripled for Cylexs ImmuKnow® Assay
10. Prodesse ProAdeno™+ Assay Cleared for US Marketing by FDA
11. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
Post Your Comments:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
Breaking Biology Technology:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):